355 related articles for article (PubMed ID: 11714622)
1. Evolutionary and immunological implications of contemporary HIV-1 variation.
Korber B; Gaschen B; Yusim K; Thakallapally R; Kesmir C; Detours V
Br Med Bull; 2001; 58():19-42. PubMed ID: 11714622
[TBL] [Abstract][Full Text] [Related]
2. Coping with viral diversity in HIV vaccine design: a response to Nickle et al.
Fischer W; Liao HX; Haynes BF; Letvin NL; Korber B
PLoS Comput Biol; 2008 Jan; 4(1):e15; author reply e25. PubMed ID: 18225944
[No Abstract] [Full Text] [Related]
3. Diversity considerations in HIV-1 vaccine selection.
Gaschen B; Taylor J; Yusim K; Foley B; Gao F; Lang D; Novitsky V; Haynes B; Hahn BH; Bhattacharya T; Korber B
Science; 2002 Jun; 296(5577):2354-60. PubMed ID: 12089434
[TBL] [Abstract][Full Text] [Related]
4. Coping with viral diversity in HIV vaccine design.
Nickle DC; Rolland M; Jensen MA; Pond SL; Deng W; Seligman M; Heckerman D; Mullins JI; Jojic N
PLoS Comput Biol; 2007 Apr; 3(4):e75. PubMed ID: 17465674
[TBL] [Abstract][Full Text] [Related]
5. Evolution of human immunodeficiency virus type 1 cytotoxic T-lymphocyte epitopes: fitness-balanced escape.
Liu Y; McNevin J; Zhao H; Tebit DM; Troyer RM; McSweyn M; Ghosh AK; Shriner D; Arts EJ; McElrath MJ; Mullins JI
J Virol; 2007 Nov; 81(22):12179-88. PubMed ID: 17728222
[TBL] [Abstract][Full Text] [Related]
6. Genotypic and phenotypic variation of HIV-1: impact on AIDS pathogenesis and vaccination.
Wolfs TF; Nara PL; Goudsmit J
Chem Immunol; 1993; 56():1-33. PubMed ID: 8383980
[No Abstract] [Full Text] [Related]
7. Rationally Designed Vaccines Targeting the V2 Region of HIV-1 gp120 Induce a Focused, Cross-Clade-Reactive, Biologically Functional Antibody Response.
Zolla-Pazner S; Powell R; Yahyaei S; Williams C; Jiang X; Li W; Lu S; Wang S; Upadhyay C; Hioe CE; Totrov M; Kong X
J Virol; 2016 Dec; 90(24):10993-11006. PubMed ID: 27630234
[TBL] [Abstract][Full Text] [Related]
8. Neutralizing epitopes in the membrane-proximal region of HIV-1 gp41: genetic variability and co-variation.
Dong XN; Chen YH
Immunol Lett; 2006 Aug; 106(2):180-6. PubMed ID: 16859756
[TBL] [Abstract][Full Text] [Related]
9. Design and construction of a recombinant epitope-peptide gene as a universal epitope-vaccine strategy.
Liu Z; Chen YH
J Immunol Methods; 2004 Feb; 285(1):93-7. PubMed ID: 14871538
[TBL] [Abstract][Full Text] [Related]
10. Clustering patterns of cytotoxic T-lymphocyte epitopes in human immunodeficiency virus type 1 (HIV-1) proteins reveal imprints of immune evasion on HIV-1 global variation.
Yusim K; Kesmir C; Gaschen B; Addo MM; Altfeld M; Brunak S; Chigaev A; Detours V; Korber BT
J Virol; 2002 Sep; 76(17):8757-68. PubMed ID: 12163596
[TBL] [Abstract][Full Text] [Related]
11. Dynamics of viral variants in HIV-1 Nef and specific cytotoxic T lymphocytes in vivo.
Haas G; Plikat U; Debré P; Lucchiari M; Katlama C; Dudoit Y; Bonduelle O; Bauer M; Ihlenfeldt HG; Jung G; Maier B; Meyerhans A; Autran B
J Immunol; 1996 Nov; 157(9):4212-21. PubMed ID: 8892659
[TBL] [Abstract][Full Text] [Related]
12. Reconstruction and function of ancestral center-of-tree human immunodeficiency virus type 1 proteins.
Rolland M; Jensen MA; Nickle DC; Yan J; Learn GH; Heath L; Weiner D; Mullins JI
J Virol; 2007 Aug; 81(16):8507-14. PubMed ID: 17537854
[TBL] [Abstract][Full Text] [Related]
13. Progress toward an artificial vaccine for HIV: identification of helper and cytotoxic T-cell epitopes and methods of immunization.
Berzofsky JA
Biotechnol Ther; 1991; 2(1-2):123-35. PubMed ID: 1726961
[TBL] [Abstract][Full Text] [Related]
14. [Evolution and Diversity of HIV-1].
Metzner KJ
Praxis (Bern 1994); 2011 Jan; 100(1):29-35. PubMed ID: 21210358
[TBL] [Abstract][Full Text] [Related]
15. Multiple Approaches for Increasing the Immunogenicity of an Epitope-Based Anti-HIV Vaccine.
Rosa DS; Ribeiro SP; Fonseca SG; Almeida RR; Santana VC; Apostólico Jde S; Kalil J; Cunha-Neto E
AIDS Res Hum Retroviruses; 2015 Nov; 31(11):1077-88. PubMed ID: 26149745
[TBL] [Abstract][Full Text] [Related]
16. Engineering immunogenic consensus T helper epitopes for a cross-clade HIV vaccine.
De Groot AS; Bishop EA; Khan B; Lally M; Marcon L; Franco J; Mayer KH; Carpenter CC; Martin W
Methods; 2004 Dec; 34(4):476-87. PubMed ID: 15542374
[TBL] [Abstract][Full Text] [Related]
17. HIV evolution in response to HLA-restricted CTL selection pressures: a population-based perspective.
Carlson JM; Brumme ZL
Microbes Infect; 2008 Apr; 10(5):455-61. PubMed ID: 18407775
[TBL] [Abstract][Full Text] [Related]
18. Ancestral and consensus envelope immunogens for HIV-1 subtype C.
Kothe DL; Li Y; Decker JM; Bibollet-Ruche F; Zammit KP; Salazar MG; Chen Y; Weng Z; Weaver EA; Gao F; Haynes BF; Shaw GM; Korber BT; Hahn BH
Virology; 2006 Sep; 352(2):438-49. PubMed ID: 16780913
[TBL] [Abstract][Full Text] [Related]
19. The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus.
Karlsson Hedestam GB; Fouchier RA; Phogat S; Burton DR; Sodroski J; Wyatt RT
Nat Rev Microbiol; 2008 Feb; 6(2):143-55. PubMed ID: 18197170
[TBL] [Abstract][Full Text] [Related]
20. Designing and engineering of DNA-vaccine construction encoding multiple CTL-epitopes of major HIV-1 antigens.
Bazhan SI; Belavin PA; Seregin SV; Danilyuk NK; Babkina IN; Karpenko LI; Nekrasova NA; Lebedev LR; Ignatyev GM; Agafonov AP; Poryvaeva VA; Aborneva IV; Ilyichev AA
Vaccine; 2004 Apr; 22(13-14):1672-82. PubMed ID: 15068850
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
